SproutNews logo

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HALL, CTMX and ENPH

NEW YORK, NY / ACCESSWIRE / June 30, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Hallmark Financial Services, Inc. (NASDAQ:HALL)
Class Period: March 5, 2019 – March 17, 2020
Lead Plaintiff Deadline: July 6, 2020

The complaint alleges that during the class period Hallmark Financial Services, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective internal controls over accounting and financial reporting related to reserves for unpaid losses; (2) the Company improperly accounted for reserve for unpaid losses and loss adjustment expenses related to its Binding Primary Commercial Auto business; (3) as a result, Hallmark Financial would be forced to report a $63.8 million loss development for prior underwriting years; (4) as a result, Hallmark Financial would exit from its Binding Primary Commercial Auto business; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in HALL: http://www.kleinstocklaw.com/pslra-1/hallmark-financial-services-inc-loss-submission-form?id=7670&from=1

CytomX Therapeutics, Inc. (NASDAQ:CTMX)
Class Period: May 17, 2018 – May 13, 2020
Lead Plaintiff Deadline: July 20, 2020

CytomX Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program; (ii) CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in CTMX: http://www.kleinstocklaw.com/pslra-1/cytomx-therapeutics-inc-loss-submission-form?id=7670&from=1

Enphase Energy, Inc. (NASDAQ:ENPH)
Class Period: February 26, 2019 – June 17, 2020
Lead Plaintiff Deadline: August 17, 2020

During the class period, Enphase Energy, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) its revenues, both U.S. and international, were inflated; (2) the Company engaged in improper deferred revenue accounting practices; (3) the Company's reported base points expansion in gross margins were overstated; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ENPH: http://www.kleinstocklaw.com/pslra-1/enphase-energy-inc-loss-submission-form?id=7670&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 595790

Go Top